Advertisement
Certain factors may help clinicians identify which patients are more likely to have greater opioid use in the first month after major surgery

Patient Factors May Predict Opioid Use After Discharge

0
Certain factors, such as anxiety, associated with greater opioid use in the month after major surgery
Supplementation with n-3 long-chain polyunsaturated fatty acids during pregnancy does not result in a lower incidence of early preterm delivery

n-3 PUFAs Do Not Lower Risk for Early Preterm Delivery

0
Maternal supplementation with n-3 long-chain polyunsaturated fatty acids did not lower risk
Allergy immunotherapy is associated with a decreased risk for asthma progression

Allergy Immunotherapy May Decrease Asthma Progression

0
Findings strongest for youngest patients with incident asthma treated in routine care
More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however

Screening for Opioid-Related Low Testosterone Underused

0
Rates of screening, treatment for low testosterone higher for prolonged versus short-term opioid users
Maintaining full doses of chemotherapy

Full Chemo Doses May Improve Survival in Breast Cancer

0
Maintaining full doses of chemo especially important early in the treatment course
Insulin pump usage has increased since 1995

Insulin Pump Therapy Use Has Increased Since 1995

0
Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years
For adults with noninfectious uveitis

Mycophenolate Mofetil Does Not Top MTX in Noninfectious Uveitis

0
Control of inflammation not superior with mycophenolate mofetil versus methotrexate
The eventual elimination of chemical testing on mammals was announced Tuesday by the U.S. Environmental Protection Agency.

EPA to Phase Out Chemical Testing on Mammals

0
Agency plans 30 percent reduction in number of studies that require use of mammals by 2025
OxyContin maker Purdue Pharma has reached a tentative settlement with a coalition of states and local governments that sued the company over its role in America's ongoing opioid crisis

Purdue Pharma Tentatively Reaches Settlement in Opioid Lawsuits

0
Deal is said to be worth $10 billion to $12 billion; company will not admit to wrongdoing
Patients with hidradenitis suppurativa have an increased risk for long-term opioid use

Risk for Long-Term Opioid Use Up in Hidradenitis Suppurativa

0
Odds higher for HS patients with advancing age, ever smoking, history of depression, comorbidity